Particularly, PHD1 inhibition or HIF-1α activity increase are thought to be effective treatments for IBD; conversely, PHD3 activity decrease or HIF-2α stability enhancement may have detrimental effects on IBD. Here, EPAS1 is linked to inflammatory bowel disease.